Alora Related Published Studies
Well-designed clinical trials related to Alora (Estradiol Transdermal)
Pharmacokinetics of testosterone and estradiol gel preparations in healthy young
men. [2013]
Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. [2011.11.29]
Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. [2011.09.24]
Prevention of menstrual migraine with perimenstrual transdermal 17-beta-estradiol: a randomized, placebo-controlled, double-blind crossover study. [2011.08]
Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition. [2011.07]
[Influence of estradiol administration mode on plasma insulin-like growth factor-I (IGF-I) and its binding proteins 1 and 3 concentration in postmenopausal women treated with norethisterone acetate]. [2011.03]
Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. [2011]
Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol
gel in Japanese women with estrogen deficiency symptoms. [2011]
Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. [2010.10]
Effects of transdermal estradiol gel and oral tibolone on health-related quality of life after surgical menopause. [2010.09]
Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes. [2010.05]
Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp. [2010.01]
Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type
determine pulsatile growth hormone secretion in healthy women: studies using
submaximal agonist drive and an estrogen clamp. [2010]
Effects of variations in serum estradiol concentrations on secretory endometrial development and function in experimentally induced cycles in normal women. [2009.12]
Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial. [2009.10]
Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women. [2009.09]
Low-dose transdermal estradiol induces breast density and heterogeneity changes comparable to those of raloxifene. [2009.07]
[Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis] [2009.07]
Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial. [2009.05]
Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium-A randomized controlled trial. [2009.01.20]
Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. [2009.01]
Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause. [2009]
Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial. [2008.12]
Estradiol treatment and its interaction with the cholinergic system: Effects on cognitive function in healthy young women. [2008.11]
Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. [2008.11]
Transdermal estradiol reduces F2alpha-isoprostane levels in postmenopausal women. [2008.07]
Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. [2008.06]
A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. [2008.05]
The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women. [2008.03]
Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. [2008]
Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women. [2007.11]
A prospective randomized comparative study of the effects of intranasal and transdermal 17 beta-estradiol on postmenopausal symptoms and vaginal cytology. [2007.10]
Lowest Effective Transdermal 17{beta}-Estradiol Dose for Relief of Hot Flushes in Postmenopausal Women: A Randomized Controlled Trial. [2007.10]
Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women. [2007.08]
One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. [2007.06.20]
A clinical trial of 3 doses of transdermal 17beta-estradiol for preventing postmenopausal bone loss: a preliminary study. [2007.05]
Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. [2007.05]
Simultaneous estradiol and levonorgestrel transdermal delivery from a 7-day patch: in vitro and in vivo drug deliveries of three formulations. [2007.04]
Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. [2007.03]
Exogenous oestradiol and progesterone administration does not cause oedema in healthy young women. [2007.03]
[Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol] [2007]
Well-designed clinical trials possibly related to Alora (Estradiol Transdermal)
Testosterone replacement therapy in older male subjective memory complainers:
double-blind randomized crossover placebo-controlled clinical trial of
physiological assessment and safety. [2015]
Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy. [2011.09.19]
Acute testosterone deprivation reduces insulin sensitivity in men. [2011.07.29]
A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders. [2011.06.30]
Hormonal replacement therapy does not affect self-estimated pain or experimental pain responses in post-menopausal women suffering from fibromyalgia: a double-blind, randomized, placebo-controlled trial. [2011.03]
Transdermal estrogen therapy effects on fibrinogen levels in women with a past history of venous thromboembolism: a pilot study. [2011]
Beneficial influence of postmenopausal estrogen therapy on serum adhesion molecules is independent of the route and dose of administration. [2011]
Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. [2010.12]
Effects of estrogen and testosterone on resting energy expenditure in older men. [2010.12]
Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. [2010.11.16]
Endometrial effect of progesterone delivered by vaginal rings in estrogen-treated postmenopausal women. [2010.10]
Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy. [2010.10]
Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy. [2010.07]
Effectiveness of hormone therapy for treating dry eye syndrome in postmenopausal women: a randomized trial. [2010.06]
Age in men does not determine gonadotropin-releasing hormone's dose-dependent stimulation of luteinizing hormone secretion under an exogenous testosterone clamp. [2010.06]
Effect of dienogest on estrogen-induced nitric oxide production in human umbilical vein endothelial cells and endothelium-dependent vasodilatation in postmenopausal women. [2010.05]
The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women. [2010.05]
Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. [2010.04]
Hormone therapy in Brazilian postmenopausal women with chronic hepatitis C: a pilot study. [2010.04]
Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. [2010.03]
Effects of exogenous testosterone supplementation in gonadotrophin stimulated cycles. [2010.03]
Neuroactive steroids after estrogen exposure in depressed postmenopausal women treated with sertraline and asymptomatic postmenopausal women. [2010.02]
Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women. [2010.02]
Sexual function in first-time contraceptive ring and contraceptive patch users. [2010.01]
[Combined hormonal contraception in cycles artificially extended]. [2010.01]
Is placebo as effective as estrogen regimens on vasomotor symptoms in women with surgical menopause? [2010]
Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive
women: A placebo-controlled trial on post-menopausal hormone therapy. [2010]
Age in men does not determine gonadotropin-releasing hormone's dose-dependent
stimulation of luteinizing hormone secretion under an exogenous testosterone
clamp. [2010]
Neuroactive steroids after estrogen exposure in depressed postmenopausal women
treated with sertraline and asymptomatic postmenopausal women. [2010]
Effect of hot flushes on vascular function: a randomized controlled trial. [2009.10]
Growth hormone and sex steroid effects on serum glucose, insulin, and lipid concentrations in healthy older women and men. [2009.10]
Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive. [2009.09]
Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women. [2009.09]
Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). [2009.09]
Effects of estrogen replacement therapy on estrogen receptor expression and immunoregulatory cytokine secretion in surgically induced menopausal women. [2009.07]
Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. [2009.05]
Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo. [2009.05]
Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. [2009.04]
Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial. [2009.02.20]
Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. [2009.02]
Hormone therapy for endometriosis and surgical menopause. [2009.01.21]
Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia. [2009.01]
Effects of long-term transdermal hormone replacement therapy on the renin-angiotensin- aldosterone system, plasma bradykinin levels and blood pressure in normotensive postmenopausal women. [2008.12]
Estrogen replacement therapy decreases plasma adiponectin but not resistin in postmenopausal women. [2008.11]
Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study. [2008.11]
Estrogen elevates the peak overnight production rate of acylated ghrelin. [2008.11]
Endometrial development and function in experimentally induced luteal phase deficiency. [2008.10]
Estrogen supplementation selectively enhances hypothalamo-pituitary sensitivity to ghrelin in postmenopausal women. [2008.10]
Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. [2008.09]
Estrogen in severe mental illness: a potential new treatment approach. [2008.08]
Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. [2008.08]
Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. [2008.08]
Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. [2008.08]
Postmenopausal estrogen therapy modulates nocturnal nonlinear heart rate dynamics. [2008.07]
Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. [2008.06]
Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. [2008.05]
One-year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. [2008.04.20]
Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women. [2008.04]
Effect of oral and transdermal hormone therapy on hyaluronic acid in women with and without a history of intrahepatic cholestasis of pregnancy. [2008.04]
Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. [2008.03]
|